Hydroxychloroquine sulfate tablets for patients with recurrent implantation failure: a double-blind, randomized, placebo-controlled trial.

ABSTRACT:

Background

Recurrent implantation failure (RIF) remains clinically unresolved at this stage. Hydroxychloroquine, as an immunomodulator, is still lacking clinical evidence, but it is being used by increasing numbers of reproductive centers and physicians worldwide, so a well-designed randomized controlled trial (RCT) is urgently needed to elucidate whether hydroxychloroquine can improve pregnancy outcomes in patients with RIF.

Methods and analysis

In this study, we plan to recruit 686 volunteers who will undergo IVF/ICSI at 5 reproductive centers from 6 December 2022. Participants will be randomized to two parallel groups and treated with hydroxychloroquine sulfate tablets or placebo from the start of endometrial preparation to 14 days after frozen embryo transfer (if not pre

SUBMITTER: Han DL 

PROVIDER: S-EPMC12933901 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature